Tumor cells, including cancer stem cells, often escape from the immune system by secreting immune inhibitory factors and creating an immunosuppressive TME to prevent recruitment and activation of DCs at the tumor site.[24, 25, 26] The development of strategies to increase cDC1 abundance in tumors or facilitate their activation will be key to boosting anti‐tumor immunity and increasing the responsiveness of cancer patients to immunotherapy. This evidence concerns the gene MPPE1 and neoplasm.